Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
about
Neuroplasticity and the next wave of antidepressant strategiesAntidepressants for depression in adults with HIV infectionDisturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric SymptomsManaging drug interactions in HIV-infected adults with comorbid illnessPharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptylineCognitive impairment in patients with AIDS - prevalence and severity.Depression in HIV infected patients: a review.Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and TreatmentInhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.Risks and benefits of late onset hypogonadism treatment: an expert opinion.Animal models for depression associated with HIV-1 infection.Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population-based cohort study.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.Comparative effectiveness of dual vs single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.Subtypes of depressive symptoms and inflammatory biomarkers: An exploratory study on a sample of HIV-positive patients.A review of drug-drug interactions in older HIV-infected patients.HIV psychiatry in the era of combined antiretroviral therapy: top five issues.Drug-drug interactions involving antidepressants: focus on desvenlafaxine.
P2860
Q21129480-5F118F76-0B87-405C-AA54-D62AEE455536Q24194669-F5B3B9FC-2B7E-4BAA-BC16-998C96A76A5DQ26800052-E4873D64-0C69-41CC-939B-E99B4AA6EAB0Q26825406-3642DC2C-4608-420A-AFB7-7E1EA73932BCQ34597852-3903084E-8E12-491A-9377-D35C38B44239Q35057500-AFE5EF31-4754-47D2-ABC2-2401E6AE6CFAQ35440924-643D4F6E-FC96-4FC0-A43E-2C682A2C66FBQ36330202-2CDFB371-BDAD-48C5-882B-E1DEB1F92707Q36571936-EAEAE64F-5C04-4251-AD56-32393CFFB991Q37165019-2638BD55-CDA4-4BE8-BFA7-88C4D8E600BEQ38171363-80AF0120-EF57-40FF-8047-22BC7C80D941Q38421984-C1A6EE84-C967-4141-A020-0EA8EEAE0DA8Q38621245-FD0ADA3A-FA70-4BA0-A4B5-05EA43CC73B2Q38878284-AC6D1593-AC19-4899-8AA7-103ACB581FFAQ40074164-1F435997-C145-475D-81BA-A0D0233E5931Q40789213-94A18C5C-1886-43CC-8000-73F346B90AC6Q41996857-D040A417-7CEB-45A7-A722-955C7EACEBB0Q43184136-236E7C4F-ED3F-487C-8D14-A4204D6E048BQ52369980-78666C8C-9C5E-49AB-8BCB-F9301A50C79D
P2860
Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacotherapy considerations ...... epressants and antipsychotics.
@en
type
label
Pharmacotherapy considerations ...... epressants and antipsychotics.
@en
prefLabel
Pharmacotherapy considerations ...... epressants and antipsychotics.
@en
P2860
P356
P1476
Pharmacotherapy considerations ...... epressants and antipsychotics.
@en
P2093
Kelly C Lee
Lucas Hill
P2860
P356
10.1345/APH.1R343
P407
P577
2013-01-22T00:00:00Z